The European Patent Office (EPO) has published patent application EP4709415A1 concerning a vaccine against the Leptospira bacterium. The patent, assigned to Intervet International B.V., was published on March 18, 2026. This publication represents the granting of a new patent for a therapeutic product.

This patent publication is primarily of interest to legal and R&D departments within pharmaceutical and biotechnology companies involved in infectious disease research and vaccine development. While it does not impose immediate compliance obligations, it signifies a new intellectual property right in the field, which may impact future market entry or licensing strategies for competitors. Companies operating in this space should be aware of this granted patent as part of their competitive intelligence and IP landscape monitoring.